Drug Interaction Study Of Filibuvir With Methadone Among Subjects On Chronic Methadone Maintenance
Completed · Phase 1
Conditions studied: Chronic Hepatitis C
In brief
Filibuvir, a CYP3A4 inhibitor is being developed for the treatment of chronic Hepatitis C infection. Given the likelihood of co administration of filibuvir and methadone, this study will evaluate the effect of filibuvir on the pharmacokinetics of R/S Methadone.
Key facts
- Study ID
- NCT01210404
- Run by
- Pfizer
- People needed
- 12
- Starts
- 2011-02-01
- Expected to finish
- 2011-06-01
- Last updated by the study team
- 2011-06-07
Who can join
Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- Males or females, without evidence of infection with HIV,HBV or HCV, who are on chronic methadone maintenance for at least three months and at a stable dose for at least 1 week prior to study start.
You may not qualify if…
- Evidence of chronic diseases including HIV, HBV or HCV.
- Evidence of acute or chronic liver disease.
- Treatment with prescription or nonprescription drugs other than methadone within 7 days.
Where it is running
- Pfizer Investigational Site — Overland Park, Kansas, United States
- Pfizer Investigational Site — Overland Park, Kansas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.